Rajkot News Today

Alzheimer’s disease Market Insights, Epidemiology, and Market Forecast-2030

 Breaking News
  • No posts were found

Alzheimer’s disease Market Insights, Epidemiology, and Market Forecast-2030

April 09
17:25 2020
Alzheimer\'s disease Market Insights, Epidemiology, and Market Forecast-2030

(Albany, US) DelveInsight has launched a new report on Alzheimer’s disease Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Alzheimer’s disease (AD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Alzheimer’s disease (AD), historical and forecasted epidemiology as well as the Alzheimer’s disease (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alzheimer’s disease (AD) market report provides current treatment practices, emerging drugs, Alzheimer’s disease (AD) market share of the individual therapies, current and forecasted Alzheimer’s disease (AD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alzheimer’s disease (AD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia (a continuous decline in thinking, behavioral and social skills that disrupts a person’s ability to function independently) accounting for ~60–80% of cases. The exact cause of Alzheimer’s disease is unknown, although a number of things are thought to increase your risk of developing the condition. These include increasing age, a family history of the condition, previous severe head injuries, and lifestyle factors and conditions associated with cardiovascular disease. The most common early symptom of Alzheimer’s is difficulty remembering newly learned information because Alzheimer’s changes typically begin in the part of the brain that affects learning.

 

 

Request for :- free sample page

Epidemiology

The Alzheimer’s disease (AD) epidemiology division provide insights about historical and current Alzheimer’s disease (AD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Report key facts:- 

1.  According to a review article entitled “Alzheimer Disease” by LianaG.Apostolovaet al., one nationally representative US data set, the Aging, Demographics, and Memory Study (ADAMS), estimated that in the United States, 14% of people of 71 years and older have dementia. Alzheimer’s Disease (AD) accounted for 70% of the dementia cases across the age spectrum in this cohort [2016].

2.   AlzheimerEuropeestimates the number of people with dementia in Germany in 2012 as being 1.92% of the total population. The number of people with dementia as a percentage of the population is somewhat higher than the EU average of 1.55%.

3. According to Alzheimer’s Association, the percentage of people with Alzheimer’s dementia increases with age: <5% of people aged 65-74, <20% of people aged 75-84, and >30% and <50% of people aged 85 and older have Alzheimer’s dementia. Out of these more than 50% are aged 75 or older [2018]

Key companies are working on this disease that are given below:-  

1. Lohmann Therapie- Systeme/ Novartis Pharma Co.
2. Green Valley Pharmaceuticals.
3. AgeneBio

Name of drugs covered are given below:-

1. Exelon
2.Oligomannate
3. AGB101

Table of content

1. Key Insights

2. Executive Summary of Alzheimer’s disease (AD)

3. Competitive Intelligence Analysis for Alzheimer’s disease (AD)

4. Alzheimer’s disease (AD): Market Overview at a Glance

4.1. Alzheimer’s disease (AD) Total Market Share (%) Distribution in 2017

4.2. Alzheimer’s disease (AD) Total Market Share (%) Distribution in 2030

5. Alzheimer’s disease (AD): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Alzheimer’s disease (AD) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Alzheimer’s disease (AD) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Alzheimer’s disease (AD) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Alzheimer’s disease (AD) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Alzheimer’s disease (AD) Treatment and Management

8.2. Alzheimer’s disease (AD) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Alzheimer’s disease (AD) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Alzheimer’s disease (AD): Seven Major Market Analysis

13.1. Key Findings

13.2. Alzheimer’s disease (AD) Market Size in 7MM

13.3. Alzheimer’s disease (AD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Alzheimer’s disease (AD) Total Market Size in the United States

15.1.2. Alzheimer’s disease (AD) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Alzheimer’s disease (AD) Total Market Size in Germany

15.3.2. Alzheimer’s disease (AD) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Alzheimer’s disease (AD) Total Market Size in France

15.4.2. Alzheimer’s disease (AD) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Alzheimer’s disease (AD) Total Market Size in Italy

15.5.2. Alzheimer’s disease (AD) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Alzheimer’s disease (AD) Total Market Size in Spain

15.6.2. Alzheimer’s disease (AD) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Alzheimer’s disease (AD) Total Market Size in the United Kingdom

15.7.2. Alzheimer’s disease (AD) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Alzheimer’s disease (AD) Total Market Size in Japan

15.8.3. Alzheimer’s disease (AD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Alzheimer’s disease (AD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Alzheimer’s disease (AD) market
  • To understand the future market competition in the Alzheimer’s disease (AD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Alzheimer’s disease (AD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Alzheimer’s disease (AD) market
  • To understand the future market competition in the Alzheimer’s disease (AD) market

Related Reports:-

1. Alzheimer’s disease (AD) – Epidemiology Forecast to 2030

2. Alzheimer’s disease (AD) – Pipeline Insights, 2020

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles